At BIO-Europe Spring in Lisbon, Martin Slezak from Lundbeck emphasized that the biotech sector is evolving to navigate added risks from geopolitical uncertainty, leading companies to prioritize resilience and late-stage assets. The market is more disciplined, with increased competition and a shift towards milestone-driven, risk-sharing deal structures, reducing reliance on upfront payments. While late-stage assets dominate interest, there remains a focus on early-stage partnerships to foster innovation globally, with Europe and China emerging as significant contributors in scientific development. Johnson & Johnson’s incubator model exemplifies efforts to support startups, although recent closures have raised questions about the future of such initiatives.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.bioxconomy.com/partnering/-expect-the-unexpected-navigating-biotech-m-a-in-an-unpredictable-climate
